Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial

HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma

(2018) George N. Ioannou et al.   JOURNAL OF HEPATOLOGY

Decreasing mortality and disease severity in hepatitis C patients awaiting liver transplantation in the United States

(2018) Allison Kwong et al.   LIVER TRANSPLANTATION

Survival in patients with Child-Pugh class C cirrhosis: Analysis of the liver transplant registry in Japan

(2017) Takuya Genda et al.   HEPATOLOGY RESEARCH

Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease

(2017) Fumihiro Ogata et al.   ONCOLOGY

Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis

(2016) Michelle C.M. Cheung et al.   JOURNAL OF HEPATOLOGY

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial

(2016) Michael Manns et al.   LANCET INFECTIOUS DISEASES

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

(2015) Michael Charlton et al.   GASTROENTEROLOGY

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis

(2015) Michael P. Curry et al.   NEW ENGLAND JOURNAL OF MEDICINE